Category Cannabis

Three separate state-level moves — Maryland’s public-health labeling discussion, Massachusetts’ near-term governance and licensing overhaul, and California’s pesticide testing rulemaking — may not look like classic headline catalysts at first glance. But for cannabis operators, labs, manufacturers, packaging vendors, distributors, and investors watching margin pressure, market access, and compliance risk, these are exactly the types of regulatory shifts that can quietly reshape the sector.

The real Aurora story in 2026 is not a vague bet on American reform. It is a much more specific and, arguably, much more investable thesis: a disciplined medical cannabis platform using Germany, Australia, EU-GMP infrastructure, and capacity expansion to build a higher-margin international business while many peers remain trapped in weaker market structures.

The most interesting part of the current cannabis setup is not a headline or a price spike. It is the possibility that the United States is slowly moving from a regime of blanket federal hostility to one of selective federal accommodation. That would be a major change. It would not, however, be the same thing as a clean legalization story.

In early March, the core question around Tilray was not whether the company could tell a big story. It was whether that story was finally becoming tangible. Q3 FY2026 does not solve every doubt, but it does move the debate forward: cannabis improved, distribution stayed strong, margins held up better than feared, adjusted EBITDA grew, and the balance sheet still looks workable. The weak point remains the same one the market keeps circling around: beverage execution and the long shadow of dilution.

ACB, TLRY, SNDL, CGC, CRON: an expanded editorial read on the best-known cannabis names, where fragile balance sheets, regulatory optionality, restructuring efforts and international medical exposure now matter more than old legalization slogans.

SNDL today is a hybrid animal: one of Canada’s largest private liquor and cannabis retailers, a vertically integrated cannabis operator and an investment platform deploying capital into the North American industry. The numbers are getting cleaner, the balance sheet is strong, but the equity story is still controversial.

Aurora Cannabis is a Canadian medical cannabis company undergoing a strategic transformation. In Q3 FY2026 (ended December 31, 2025), Aurora reported estimated $94.2M CAD in net revenue (+7% YoY), with record medical cannabis revenue of $76.2M CAD (+12% YoY). The company is pivoting aggressively toward high-margin global medical markets (especially Germany, Poland, Australia, UK), exiting lower-margin consumer segments in Canada, and divesting its plant propagation business.